Q-omics provides the consensus-scored KLK8 profile across patient tissues and cancer cell-line models. KLK8 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KLK8 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, KLK8 RNA expression shows 12,008 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, COAD, and ESCA as cancer lineages where KLK8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLK8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLK8 survival associations across molecular data types. KLK8 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLK8 RNA expression–survival associations across cancer types. High KLK8 expression shows unfavorable associations in KIRC, BLCA, SKCM, KIRP, LUAD and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KLK8 RNA expression.
This table summarizes KLK8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for KLK8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLK8 shows lower tumor expression in BRCA and KIRC and higher tumor expression in COAD, LUSC, LUAD and THCA. The COAD box plot shows higher KLK8 RNA expression in tumor versus normal tissue (log2 FC = +2.014, t-test p < 0.001).
This table shows molecular features associated with KLK8 in patient tissues and cancer cell lines. In patient samples, KLK8 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, KLK8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and OVARY.
